AstraZeneca shares dip after $39 bln Alexion deal

AstraZeneca shares fell on Monday, as investors moved to price in the British drugmaker's $39 billion deal for U.S. biotech firm Alexion Pharmaceuticals, the company's largest ever takeover and one of this year's biggest mergers globally.

---